NC
AQST icon

NewSquare Capital’s Aquestive Therapeutics AQST Stock Holding History

NewSquare Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-130
Closed -$215 – 610
2023
Q2 		$215 Hold
130
– – ﹤0.01% 753
2023
Q1 		$148 Hold
130
– – ﹤0.01% 804
2022
Q4 		$117 Buy
+130
New +$122 ﹤0.01% 760

Other funds holding AQST

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

NewSquare Capital's AQST Position: Q3 2023 in Review

NewSquare Capital sold out of Aquestive Therapeutics (AQST) in Q3 2023, closing a stake of 130 shares — an estimated $215 sold.

NewSquare Capital first reported a position in AQST in Q4 2022 and held it in 3 quarters. The position peaked at $215 in Q2 2023. 47 funds tracked by Wall St. Rank hold AQST as of Q3 2023.

  • NewSquare Capital reported no remaining Aquestive Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 130 Aquestive Therapeutics shares in Q3 2023, an estimated $215.
  • NewSquare Capital first reported a position in Aquestive Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Aquestive Therapeutics position peaked at $215 in Q2 2023.
  • 47 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.